SlideShare ist ein Scribd-Unternehmen logo
1 von 5
Downloaden Sie, um offline zu lesen
DEPARTMENT OF HEALTH & HUMAN SERVICES                              Public Health Service



                                                                         Food and Drug Administration
                                                                         Silver Spring, MD 20993

TRANSMITTED BY FACSIMILE

Fadwa Almanakly
Associate Director, Global Regulatory Affairs
Bayer Healthcare Pharmaceuticals, Incorporated
6 West Belt-W13
Wayne, NJ 07470

RE:     NDA No. 21-400 LEVITRA® (vardenafil HCl) Tablets
        NDA No. 21-676, 21-873, 22-045 YAZ® (drospirenone and ethinyl estradiol)
        Tablets
        NDA No. 21-225 Mirena® (levonorgestrel-releasing intrauterine system)
        MACMIS ID # 17307

Dear Ms. Almanakly:

This letter notifies Bayer Healthcare Pharmaceuticals, Incorporated (Bayer), and, by copy,
Schering Corporation (Schering), which markets Levitra on behalf of Bayer, that, as part of its
monitoring and surveillance program, the Division of Drug Marketing, Advertising, and
Communications (DDMAC) of the U.S. Food and Drug Administration (FDA) has reviewed
Bayer’s sponsored links on internet search engines (e.g., Google.com) for the following
products: LEVITRA® (vardenafil HCl) Tablets (Levitra), YAZ® (drospirenone and ethinyl
estradiol) Tablets (YAZ), and Mirena® (levonorgestrel-releasing intrauterine system) (Mirena).
The sponsored links cited in this letter are misleading because they make representations
and/or suggestions about the efficacy of Levitra, YAZ, and Mirena, but fail to communicate
any risk information associated with the use of these drugs. In addition, the sponsored links
for YAZ and Mirena inadequately communicate the drugs’ indications, and the sponsored
links for Mirena overstate the efficacy of the drug. Furthermore, all of the sponsored links fail
to use the required established name. Thus, the sponsored links misbrand the drugs in
violation of the Federal Food, Drug, and Cosmetic Act (the Act) and FDA implementing
regulations. See 21 U.S.C. 352(a) & (n), 321(n); 21 CFR 201.10(g)(1), 202.1(b)(1), (e)(3)(i),
(ii) & (e)(6)(i).

Background

Levitra
According to its FDA-approved product labeling (PI), Levitra is indicated for the treatment of
erectile dysfunction.

Levitra is associated with a number of risks, as reflected in the Contraindications, Warnings,
Precautions, and Adverse Reactions sections of its PI.
Fadwa Almanakly                                                             Page 2
Bayer Healthcare Pharmaceuticals Incorporated
NDA#21-400, 21-676, 21-873, 22-045, 21-225
MACMIS#17307

YAZ
According to its FDA-approved PI, YAZ is indicated for the prevention of pregnancy in women
who elect to use an oral contraceptive.

YAZ is also indicated for the treatment of symptoms of premenstrual dysphoric disorder
(PMDD) in women who choose to use an oral contraceptive as their method of contraception.
The effectiveness of YAZ for PMDD when used for more than three menstrual cycles has not
been evaluated.

YAZ has not been evaluated for the treatment of premenstrual syndrome (PMS).

YAZ is also indicated for the treatment of moderate acne vulgaris in women at least 14 years
of age, who have no known contraindications to oral contraceptive therapy, and have
achieved menarche. YAZ should be used for the treatment of acne only if the patient desires
an oral contraceptive for birth control.

YAZ is associated with a number of risks, as reflected in the Boxed Warning,
Contraindications, Warnings, Precautions, and Adverse Reactions sections of its PI.

Mirena
According to its FDA-approved PI, Mirena is indicated for intrauterine contraception for up to
5 years. Thereafter, if continued contraception is desired, the system should be replaced.

Mirena is recommended for women who have had at least one child.

Mirena is associated with a number of risks, as reflected in the Contraindications, Warnings,
Precautions, and Adverse Reactions sections of its PI.

Omission of Risk Information

Promotional materials, other than reminder pieces, which include the name of the drug
product but do not include indications or other representations or suggestions relative to the
drug product (see 21 CFR 200.200, 201.100(f), 202.1(e)(2)(i)), are required to disclose risk
and other information about the drug. Such materials are misleading if they fail to reveal
facts that are material in light of the representations made by the materials or with respect to
consequences that may result from the use of the drug as recommended or suggested by the
materials. The sponsored links present the following claims:

   •	 Poor Blood Flow & ED
      www.LEVITRA.com Blood Flow May Decrease With High Blood Pressure And May
      Lead to ED.

   •	 YAZ® Birth Control Pill

      www.Yaz-US.com YAZ® Prevents Pregnancy, May Help Moderate Acne and 

      PMDD.
Fadwa Almanakly                                                              Page 3
Bayer Healthcare Pharmaceuticals Incorporated
NDA#21-400, 21-676, 21-873, 22-045, 21-225
MACMIS#17307

   •	 Mirena® Birth Control
      www.Mirena-US.com Mirena® - Effective Birth Control That Helps Keep Life Simple.

   •	 Anticonceptivo Mirena

      Descubre La Flexibilidad de Mirena Más Informacion en Espanol Aqui

                                                                        

      www.SimplementeMirena.com 


These sponsored links make representations and/or suggestions about the efficacy of
Levitra, YAZ, and Mirena, respectively, but fail to communicate any risk information. This
omission of risk information is particularly concerning as one of these products, YAZ, has a
Boxed Warning. For promotional materials to be truthful and non-misleading, they must
contain risk information in each part as necessary to qualify any claims made about the drug.

By omitting the most serious and frequently occurring risks associated with the drugs
promoted in the links above, the sponsored links misleadingly suggest that Levitra, YAZ, and
Mirena are safer than has been demonstrated. We note that these sponsored links contain a
link to the products’ websites. However, this is insufficient to mitigate the misleading
omission of risk information from these promotional materials.

Inadequate Communication of Indication/Overstatement of Efficacy

The sponsored link for YAZ provides a very brief statement about what the drug is for;
however, this statement is incomplete and misleading, suggesting that YAZ is useful in a
broader range of conditions or patients than has been demonstrated by substantial evidence
or substantial clinical experience. Specifically, the sponsored link for YAZ misleadingly
broadens the indication for YAZ by implying that all patients with moderate acne are
candidates for YAZ therapy (“YAZ® Prevents Pregnancy, May Help Moderate Acne and
PMDD”), when this is not the case. Rather, YAZ’s indication is limited to the treatment of
moderate acne vulgaris in women at least 14 years of age who have achieved menarche,
and it should be used for the treatment of acne only if the patient desires an oral
contraceptive for birth control.

The sponsored links for Mirena overstate the efficacy for Mirena by failing to reveal that
Mirena is only indicated for up to 5 years of use before replacement. By omitting this
information, the link suggests that the drug can be used indefinitely, when this is not the case.
Likewise, the sponsored links for Mirena provide very brief statements about what the drug is
for; however, these statements are incomplete and misleading in that they fail to convey the
recommended patient population for Mirena (women who have had at least one child), thus
suggesting that the drug is appropriate for any woman.

Failure to Use Required Established Name

None of the sponsored links present the full established name of the drugs being promoted,
despite the requirement to do so. See 21 CFR 201.10(g)(1) & 202.1(b)(1).
Fadwa Almanakly                                                                Page 4
Bayer Healthcare Pharmaceuticals Incorporated
NDA#21-400, 21-676, 21-873, 22-045, 21-225
MACMIS#17307

Conclusions and Requested Action

For the reasons discussed above, the sponsored links misbrand Levitra, YAZ, and Mirena in
violation of the Act and FDA regulations. See 21 U.S.C. 352(a) & (n), 321(n); 21 CFR
201.10(g)(1), 202.1(b)(1), (e)(3)(i), (ii) & (e)(6)(i).

DDMAC requests that Bayer immediately cease the dissemination of violative promotional
materials for Levitra, YAZ, and Mirena, such as those described above. Please submit a
written response to this letter on or before April 9, 2009, stating whether you intend to comply
with this request, listing all promotional materials (with the 2253 submission date) in use for
these drugs as of the date of this letter, identifying which of these materials contain violations
such as those described above, and explaining your plan for discontinuing use of such
materials. Finally, we encourage you to review your promotional materials for the other
prescription drug products that Bayer promotes in the United States and to discontinue or
revise any materials with the same or similar violations, and request that your response
address this issue as well.

Please direct your response to the undersigned at the Food and Drug Administration, Center
for Drug Evaluation and Research, Division of Drug Marketing, Advertising, and
Communications, 5901-B Ammendale Road, Beltsville, MD, facsimile at 301-847-8444. In all
future correspondence regarding this matter, please refer to MACMIS # 17307 in addition to
the NDA numbers. We remind you that only written communications are considered official.

The violations discussed in this letter do not necessarily constitute an exhaustive list. It is
your responsibility to ensure that your promotional materials for Levitra, YAZ, and Mirena
comply with each applicable requirement of the Act and FDA implementing regulations.




                                                  Sincerely,        


                                                  {See appended electronic signature page}


                                                  Shefali Doshi, M.D. 

                                                  Regulatory Review Officer

                                                  Division of Drug Marketing,

                                                  Advertising, and Communications 




cc: Casilda Luck-Barnes
    Senior Manager, Global Regulatory Affairs
    Schering Corporation
    2000 Galloping Hill Road
    Kenilworth, NJ 07033
---------------------------------------------------------------------------------------------------------------------
This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.
---------------------------------------------------------------------------------------------------------------------
  /s/

---------------------
Shefali Doshi

3/26/2009 04:39:41 PM

Más contenido relacionado

Andere mochten auch

Assignments That Matter
Assignments That MatterAssignments That Matter
Assignments That MatterAbby
 
Social Studies Visual --Lord of the Streets
Social Studies Visual --Lord of the StreetsSocial Studies Visual --Lord of the Streets
Social Studies Visual --Lord of the Streetsguest6c9154f
 
Creative Revenue Generation
Creative Revenue GenerationCreative Revenue Generation
Creative Revenue Generationlgdeaton
 
DBSight Introduction
DBSight IntroductionDBSight Introduction
DBSight Introductionchrislusf
 
DBSight Scalability
DBSight ScalabilityDBSight Scalability
DBSight Scalabilitychrislusf
 

Andere mochten auch (8)

2008 Yaz Warning
2008 Yaz Warning2008 Yaz Warning
2008 Yaz Warning
 
Assignments That Matter
Assignments That MatterAssignments That Matter
Assignments That Matter
 
Social Studies Visual --Lord of the Streets
Social Studies Visual --Lord of the StreetsSocial Studies Visual --Lord of the Streets
Social Studies Visual --Lord of the Streets
 
Star Chart
Star ChartStar Chart
Star Chart
 
Creative Revenue Generation
Creative Revenue GenerationCreative Revenue Generation
Creative Revenue Generation
 
P A T A X
P A T A XP A T A X
P A T A X
 
DBSight Introduction
DBSight IntroductionDBSight Introduction
DBSight Introduction
 
DBSight Scalability
DBSight ScalabilityDBSight Scalability
DBSight Scalability
 

Ähnlich wie 2009 Yaz Warning

Lessons Learned from the Ethical Challenges of Marketing in Healthcare
Lessons Learned from the Ethical Challenges of Marketing in HealthcareLessons Learned from the Ethical Challenges of Marketing in Healthcare
Lessons Learned from the Ethical Challenges of Marketing in HealthcareSandeepkumar Balabbigari, PharmD, RPh
 
Direct To Consumer Drug Advertising
Direct To Consumer Drug AdvertisingDirect To Consumer Drug Advertising
Direct To Consumer Drug Advertisingguest78c907
 
MHC 750 JH 01 Direct To Consumer Drug Advertising
MHC 750 JH 01 Direct To Consumer Drug AdvertisingMHC 750 JH 01 Direct To Consumer Drug Advertising
MHC 750 JH 01 Direct To Consumer Drug AdvertisingLeslie Pirtle, MM, MEd
 
D T C Advertising
D T C AdvertisingD T C Advertising
D T C Advertisingguest78c907
 
Dr. DelConte\'s Presentation
Dr. DelConte\'s PresentationDr. DelConte\'s Presentation
Dr. DelConte\'s Presentationmjfanelli
 
VIAGRA: Wonder Drug or Ethical Irresponsibility?
VIAGRA: Wonder Drug or Ethical Irresponsibility?VIAGRA: Wonder Drug or Ethical Irresponsibility?
VIAGRA: Wonder Drug or Ethical Irresponsibility?tofugirl
 
Critique a TV or radio commercial, an Internet advertisement, or a.docx
Critique a TV or radio commercial, an Internet advertisement, or a.docxCritique a TV or radio commercial, an Internet advertisement, or a.docx
Critique a TV or radio commercial, an Internet advertisement, or a.docxwilliejgrant41084
 
REMS: the long tail can sting you
REMS: the long tail can sting youREMS: the long tail can sting you
REMS: the long tail can sting youDavid Levin
 
A succsess story for rationing
A succsess story for rationingA succsess story for rationing
A succsess story for rationingelifkizanlikli
 
Pharma Uptoday Monthly Magazine - Volume 11, Issue Feb 2015
Pharma Uptoday Monthly Magazine - Volume 11, Issue Feb 2015Pharma Uptoday Monthly Magazine - Volume 11, Issue Feb 2015
Pharma Uptoday Monthly Magazine - Volume 11, Issue Feb 2015Sathish Vemula
 
similarities_differences_brandname_generic_drugs_e.pdf
similarities_differences_brandname_generic_drugs_e.pdfsimilarities_differences_brandname_generic_drugs_e.pdf
similarities_differences_brandname_generic_drugs_e.pdfShivenduShekhar6
 
Direct to Consumer Advertising Presentation
Direct to Consumer Advertising PresentationDirect to Consumer Advertising Presentation
Direct to Consumer Advertising Presentationcstam
 
Crofelemer letter salix and napo 2012
Crofelemer letter salix and napo 2012Crofelemer letter salix and napo 2012
Crofelemer letter salix and napo 2012Bhumi Patel
 
Use of testimonials and endorsements in prescription drug advertisements
Use of testimonials and endorsements in prescription drug advertisementsUse of testimonials and endorsements in prescription drug advertisements
Use of testimonials and endorsements in prescription drug advertisementsFreedom Monk
 
Recommend one one and one nonpharmacological.docx
Recommend one one and one nonpharmacological.docxRecommend one one and one nonpharmacological.docx
Recommend one one and one nonpharmacological.docxwrite30
 
Trivexa.pdf
Trivexa.pdfTrivexa.pdf
Trivexa.pdfmarwin30
 
Generic Medication vs Brand name
Generic Medication vs Brand nameGeneric Medication vs Brand name
Generic Medication vs Brand namegarreth mulany
 
Qui Tam: Off Label Drug Marketing [Data Snapshot]
Qui Tam: Off Label Drug Marketing [Data Snapshot]Qui Tam: Off Label Drug Marketing [Data Snapshot]
Qui Tam: Off Label Drug Marketing [Data Snapshot]lawsuitlegal
 
FDA Regulation of Promotion & Advertising-- Part 6A: Draft Guidance on Medica...
FDA Regulation of Promotion & Advertising-- Part 6A: Draft Guidance on Medica...FDA Regulation of Promotion & Advertising-- Part 6A: Draft Guidance on Medica...
FDA Regulation of Promotion & Advertising-- Part 6A: Draft Guidance on Medica...Michael Swit
 

Ähnlich wie 2009 Yaz Warning (20)

Lessons Learned from the Ethical Challenges of Marketing in Healthcare
Lessons Learned from the Ethical Challenges of Marketing in HealthcareLessons Learned from the Ethical Challenges of Marketing in Healthcare
Lessons Learned from the Ethical Challenges of Marketing in Healthcare
 
Direct To Consumer Drug Advertising
Direct To Consumer Drug AdvertisingDirect To Consumer Drug Advertising
Direct To Consumer Drug Advertising
 
MHC 750 JH 01 Direct To Consumer Drug Advertising
MHC 750 JH 01 Direct To Consumer Drug AdvertisingMHC 750 JH 01 Direct To Consumer Drug Advertising
MHC 750 JH 01 Direct To Consumer Drug Advertising
 
D T C Advertising
D T C AdvertisingD T C Advertising
D T C Advertising
 
Dr. DelConte\'s Presentation
Dr. DelConte\'s PresentationDr. DelConte\'s Presentation
Dr. DelConte\'s Presentation
 
VIAGRA: Wonder Drug or Ethical Irresponsibility?
VIAGRA: Wonder Drug or Ethical Irresponsibility?VIAGRA: Wonder Drug or Ethical Irresponsibility?
VIAGRA: Wonder Drug or Ethical Irresponsibility?
 
Critique a TV or radio commercial, an Internet advertisement, or a.docx
Critique a TV or radio commercial, an Internet advertisement, or a.docxCritique a TV or radio commercial, an Internet advertisement, or a.docx
Critique a TV or radio commercial, an Internet advertisement, or a.docx
 
REMS: the long tail can sting you
REMS: the long tail can sting youREMS: the long tail can sting you
REMS: the long tail can sting you
 
A succsess story for rationing
A succsess story for rationingA succsess story for rationing
A succsess story for rationing
 
Pharma Uptoday Monthly Magazine - Volume 11, Issue Feb 2015
Pharma Uptoday Monthly Magazine - Volume 11, Issue Feb 2015Pharma Uptoday Monthly Magazine - Volume 11, Issue Feb 2015
Pharma Uptoday Monthly Magazine - Volume 11, Issue Feb 2015
 
similarities_differences_brandname_generic_drugs_e.pdf
similarities_differences_brandname_generic_drugs_e.pdfsimilarities_differences_brandname_generic_drugs_e.pdf
similarities_differences_brandname_generic_drugs_e.pdf
 
Direct to Consumer Advertising Presentation
Direct to Consumer Advertising PresentationDirect to Consumer Advertising Presentation
Direct to Consumer Advertising Presentation
 
Crofelemer letter salix and napo 2012
Crofelemer letter salix and napo 2012Crofelemer letter salix and napo 2012
Crofelemer letter salix and napo 2012
 
Use of testimonials and endorsements in prescription drug advertisements
Use of testimonials and endorsements in prescription drug advertisementsUse of testimonials and endorsements in prescription drug advertisements
Use of testimonials and endorsements in prescription drug advertisements
 
Recommend one one and one nonpharmacological.docx
Recommend one one and one nonpharmacological.docxRecommend one one and one nonpharmacological.docx
Recommend one one and one nonpharmacological.docx
 
Trivexa.pdf
Trivexa.pdfTrivexa.pdf
Trivexa.pdf
 
Generic Medication vs Brand name
Generic Medication vs Brand nameGeneric Medication vs Brand name
Generic Medication vs Brand name
 
Qui Tam: Off Label Drug Marketing [Data Snapshot]
Qui Tam: Off Label Drug Marketing [Data Snapshot]Qui Tam: Off Label Drug Marketing [Data Snapshot]
Qui Tam: Off Label Drug Marketing [Data Snapshot]
 
FDA Regulation of Promotion & Advertising-- Part 6A: Draft Guidance on Medica...
FDA Regulation of Promotion & Advertising-- Part 6A: Draft Guidance on Medica...FDA Regulation of Promotion & Advertising-- Part 6A: Draft Guidance on Medica...
FDA Regulation of Promotion & Advertising-- Part 6A: Draft Guidance on Medica...
 
Natural Weight Loss Su
Natural Weight Loss SuNatural Weight Loss Su
Natural Weight Loss Su
 

Último

SGK PHÙ PHỔI CẤP ĐHYHN .pdf
SGK PHÙ PHỔI CẤP ĐHYHN                   .pdfSGK PHÙ PHỔI CẤP ĐHYHN                   .pdf
SGK PHÙ PHỔI CẤP ĐHYHN .pdfHongBiThi1
 
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on time
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on timeTracheostomy .pdf ENT by QuickMedTALK. getting things done on time
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on timeQuick MedTalk
 
bleeding disorders 1 Dr.Nannika Pradhan
bleeding disorders 1  Dr.Nannika Pradhanbleeding disorders 1  Dr.Nannika Pradhan
bleeding disorders 1 Dr.Nannika Pradhanthesalberry
 
SGK VIÊM KHỚP DẠNG THẤP YHN .pdf
SGK VIÊM KHỚP DẠNG THẤP YHN              .pdfSGK VIÊM KHỚP DẠNG THẤP YHN              .pdf
SGK VIÊM KHỚP DẠNG THẤP YHN .pdfHongBiThi1
 
Methicillin-resistant Staphylococcus Aureus (MRSA)
Methicillin-resistant Staphylococcus Aureus (MRSA)Methicillin-resistant Staphylococcus Aureus (MRSA)
Methicillin-resistant Staphylococcus Aureus (MRSA)Ahmad Thanin
 
Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......anupamdas2143
 
clean rooms and its classification .pptx
clean rooms and its classification .pptxclean rooms and its classification .pptx
clean rooms and its classification .pptxushakiranmai4
 
Derma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech LimitedDerma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech LimitedSBL DIGITAL
 
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptxANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptxsiddharthroy26587
 
Neurological Evaluation of Acute Ischemic stroke in Emergency Room
Neurological Evaluation of Acute Ischemic stroke in Emergency RoomNeurological Evaluation of Acute Ischemic stroke in Emergency Room
Neurological Evaluation of Acute Ischemic stroke in Emergency RoomSudhir Kumar
 
Thyroid function tests for MBBS, LAB. MED & BDS.pptx
Thyroid function tests for MBBS, LAB. MED & BDS.pptxThyroid function tests for MBBS, LAB. MED & BDS.pptx
Thyroid function tests for MBBS, LAB. MED & BDS.pptxRajendra Dev Bhatt
 
Brief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptxBrief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptxTina Purnat
 
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptxNECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptxSizan Thapa
 
The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...JakeMatthews12
 
Explaining "pathology" in digital pathology
Explaining "pathology" in digital pathologyExplaining "pathology" in digital pathology
Explaining "pathology" in digital pathologyYves Sucaet
 
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdfSGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdfHongBiThi1
 
TARGET DELINEATION IN RECTUM CANCER BY DR KANHU
TARGET DELINEATION IN RECTUM  CANCER BY DR KANHUTARGET DELINEATION IN RECTUM  CANCER BY DR KANHU
TARGET DELINEATION IN RECTUM CANCER BY DR KANHUKanhu Charan
 
Basic of Thyroid Hormone:- An In-depth Analysis
Basic of Thyroid Hormone:- An In-depth AnalysisBasic of Thyroid Hormone:- An In-depth Analysis
Basic of Thyroid Hormone:- An In-depth AnalysisAshishMaletha2
 
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptxCholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptxRajendra Dev Bhatt
 
Ten lessons learnt as anesthetist.pptx
Ten  lessons  learnt as anesthetist.pptxTen  lessons  learnt as anesthetist.pptx
Ten lessons learnt as anesthetist.pptxtusharchokshi1
 

Último (20)

SGK PHÙ PHỔI CẤP ĐHYHN .pdf
SGK PHÙ PHỔI CẤP ĐHYHN                   .pdfSGK PHÙ PHỔI CẤP ĐHYHN                   .pdf
SGK PHÙ PHỔI CẤP ĐHYHN .pdf
 
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on time
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on timeTracheostomy .pdf ENT by QuickMedTALK. getting things done on time
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on time
 
bleeding disorders 1 Dr.Nannika Pradhan
bleeding disorders 1  Dr.Nannika Pradhanbleeding disorders 1  Dr.Nannika Pradhan
bleeding disorders 1 Dr.Nannika Pradhan
 
SGK VIÊM KHỚP DẠNG THẤP YHN .pdf
SGK VIÊM KHỚP DẠNG THẤP YHN              .pdfSGK VIÊM KHỚP DẠNG THẤP YHN              .pdf
SGK VIÊM KHỚP DẠNG THẤP YHN .pdf
 
Methicillin-resistant Staphylococcus Aureus (MRSA)
Methicillin-resistant Staphylococcus Aureus (MRSA)Methicillin-resistant Staphylococcus Aureus (MRSA)
Methicillin-resistant Staphylococcus Aureus (MRSA)
 
Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......
 
clean rooms and its classification .pptx
clean rooms and its classification .pptxclean rooms and its classification .pptx
clean rooms and its classification .pptx
 
Derma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech LimitedDerma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech Limited
 
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptxANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
 
Neurological Evaluation of Acute Ischemic stroke in Emergency Room
Neurological Evaluation of Acute Ischemic stroke in Emergency RoomNeurological Evaluation of Acute Ischemic stroke in Emergency Room
Neurological Evaluation of Acute Ischemic stroke in Emergency Room
 
Thyroid function tests for MBBS, LAB. MED & BDS.pptx
Thyroid function tests for MBBS, LAB. MED & BDS.pptxThyroid function tests for MBBS, LAB. MED & BDS.pptx
Thyroid function tests for MBBS, LAB. MED & BDS.pptx
 
Brief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptxBrief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptx
 
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptxNECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
 
The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...
 
Explaining "pathology" in digital pathology
Explaining "pathology" in digital pathologyExplaining "pathology" in digital pathology
Explaining "pathology" in digital pathology
 
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdfSGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
 
TARGET DELINEATION IN RECTUM CANCER BY DR KANHU
TARGET DELINEATION IN RECTUM  CANCER BY DR KANHUTARGET DELINEATION IN RECTUM  CANCER BY DR KANHU
TARGET DELINEATION IN RECTUM CANCER BY DR KANHU
 
Basic of Thyroid Hormone:- An In-depth Analysis
Basic of Thyroid Hormone:- An In-depth AnalysisBasic of Thyroid Hormone:- An In-depth Analysis
Basic of Thyroid Hormone:- An In-depth Analysis
 
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptxCholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptx
 
Ten lessons learnt as anesthetist.pptx
Ten  lessons  learnt as anesthetist.pptxTen  lessons  learnt as anesthetist.pptx
Ten lessons learnt as anesthetist.pptx
 

2009 Yaz Warning

  • 1. DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993 TRANSMITTED BY FACSIMILE Fadwa Almanakly Associate Director, Global Regulatory Affairs Bayer Healthcare Pharmaceuticals, Incorporated 6 West Belt-W13 Wayne, NJ 07470 RE: NDA No. 21-400 LEVITRA® (vardenafil HCl) Tablets NDA No. 21-676, 21-873, 22-045 YAZ® (drospirenone and ethinyl estradiol) Tablets NDA No. 21-225 Mirena® (levonorgestrel-releasing intrauterine system) MACMIS ID # 17307 Dear Ms. Almanakly: This letter notifies Bayer Healthcare Pharmaceuticals, Incorporated (Bayer), and, by copy, Schering Corporation (Schering), which markets Levitra on behalf of Bayer, that, as part of its monitoring and surveillance program, the Division of Drug Marketing, Advertising, and Communications (DDMAC) of the U.S. Food and Drug Administration (FDA) has reviewed Bayer’s sponsored links on internet search engines (e.g., Google.com) for the following products: LEVITRA® (vardenafil HCl) Tablets (Levitra), YAZ® (drospirenone and ethinyl estradiol) Tablets (YAZ), and Mirena® (levonorgestrel-releasing intrauterine system) (Mirena). The sponsored links cited in this letter are misleading because they make representations and/or suggestions about the efficacy of Levitra, YAZ, and Mirena, but fail to communicate any risk information associated with the use of these drugs. In addition, the sponsored links for YAZ and Mirena inadequately communicate the drugs’ indications, and the sponsored links for Mirena overstate the efficacy of the drug. Furthermore, all of the sponsored links fail to use the required established name. Thus, the sponsored links misbrand the drugs in violation of the Federal Food, Drug, and Cosmetic Act (the Act) and FDA implementing regulations. See 21 U.S.C. 352(a) & (n), 321(n); 21 CFR 201.10(g)(1), 202.1(b)(1), (e)(3)(i), (ii) & (e)(6)(i). Background Levitra According to its FDA-approved product labeling (PI), Levitra is indicated for the treatment of erectile dysfunction. Levitra is associated with a number of risks, as reflected in the Contraindications, Warnings, Precautions, and Adverse Reactions sections of its PI.
  • 2. Fadwa Almanakly Page 2 Bayer Healthcare Pharmaceuticals Incorporated NDA#21-400, 21-676, 21-873, 22-045, 21-225 MACMIS#17307 YAZ According to its FDA-approved PI, YAZ is indicated for the prevention of pregnancy in women who elect to use an oral contraceptive. YAZ is also indicated for the treatment of symptoms of premenstrual dysphoric disorder (PMDD) in women who choose to use an oral contraceptive as their method of contraception. The effectiveness of YAZ for PMDD when used for more than three menstrual cycles has not been evaluated. YAZ has not been evaluated for the treatment of premenstrual syndrome (PMS). YAZ is also indicated for the treatment of moderate acne vulgaris in women at least 14 years of age, who have no known contraindications to oral contraceptive therapy, and have achieved menarche. YAZ should be used for the treatment of acne only if the patient desires an oral contraceptive for birth control. YAZ is associated with a number of risks, as reflected in the Boxed Warning, Contraindications, Warnings, Precautions, and Adverse Reactions sections of its PI. Mirena According to its FDA-approved PI, Mirena is indicated for intrauterine contraception for up to 5 years. Thereafter, if continued contraception is desired, the system should be replaced. Mirena is recommended for women who have had at least one child. Mirena is associated with a number of risks, as reflected in the Contraindications, Warnings, Precautions, and Adverse Reactions sections of its PI. Omission of Risk Information Promotional materials, other than reminder pieces, which include the name of the drug product but do not include indications or other representations or suggestions relative to the drug product (see 21 CFR 200.200, 201.100(f), 202.1(e)(2)(i)), are required to disclose risk and other information about the drug. Such materials are misleading if they fail to reveal facts that are material in light of the representations made by the materials or with respect to consequences that may result from the use of the drug as recommended or suggested by the materials. The sponsored links present the following claims: • Poor Blood Flow & ED www.LEVITRA.com Blood Flow May Decrease With High Blood Pressure And May Lead to ED. • YAZ® Birth Control Pill www.Yaz-US.com YAZ® Prevents Pregnancy, May Help Moderate Acne and PMDD.
  • 3. Fadwa Almanakly Page 3 Bayer Healthcare Pharmaceuticals Incorporated NDA#21-400, 21-676, 21-873, 22-045, 21-225 MACMIS#17307 • Mirena® Birth Control www.Mirena-US.com Mirena® - Effective Birth Control That Helps Keep Life Simple. • Anticonceptivo Mirena Descubre La Flexibilidad de Mirena Más Informacion en Espanol Aqui   www.SimplementeMirena.com These sponsored links make representations and/or suggestions about the efficacy of Levitra, YAZ, and Mirena, respectively, but fail to communicate any risk information. This omission of risk information is particularly concerning as one of these products, YAZ, has a Boxed Warning. For promotional materials to be truthful and non-misleading, they must contain risk information in each part as necessary to qualify any claims made about the drug. By omitting the most serious and frequently occurring risks associated with the drugs promoted in the links above, the sponsored links misleadingly suggest that Levitra, YAZ, and Mirena are safer than has been demonstrated. We note that these sponsored links contain a link to the products’ websites. However, this is insufficient to mitigate the misleading omission of risk information from these promotional materials. Inadequate Communication of Indication/Overstatement of Efficacy The sponsored link for YAZ provides a very brief statement about what the drug is for; however, this statement is incomplete and misleading, suggesting that YAZ is useful in a broader range of conditions or patients than has been demonstrated by substantial evidence or substantial clinical experience. Specifically, the sponsored link for YAZ misleadingly broadens the indication for YAZ by implying that all patients with moderate acne are candidates for YAZ therapy (“YAZ® Prevents Pregnancy, May Help Moderate Acne and PMDD”), when this is not the case. Rather, YAZ’s indication is limited to the treatment of moderate acne vulgaris in women at least 14 years of age who have achieved menarche, and it should be used for the treatment of acne only if the patient desires an oral contraceptive for birth control. The sponsored links for Mirena overstate the efficacy for Mirena by failing to reveal that Mirena is only indicated for up to 5 years of use before replacement. By omitting this information, the link suggests that the drug can be used indefinitely, when this is not the case. Likewise, the sponsored links for Mirena provide very brief statements about what the drug is for; however, these statements are incomplete and misleading in that they fail to convey the recommended patient population for Mirena (women who have had at least one child), thus suggesting that the drug is appropriate for any woman. Failure to Use Required Established Name None of the sponsored links present the full established name of the drugs being promoted, despite the requirement to do so. See 21 CFR 201.10(g)(1) & 202.1(b)(1).
  • 4. Fadwa Almanakly Page 4 Bayer Healthcare Pharmaceuticals Incorporated NDA#21-400, 21-676, 21-873, 22-045, 21-225 MACMIS#17307 Conclusions and Requested Action For the reasons discussed above, the sponsored links misbrand Levitra, YAZ, and Mirena in violation of the Act and FDA regulations. See 21 U.S.C. 352(a) & (n), 321(n); 21 CFR 201.10(g)(1), 202.1(b)(1), (e)(3)(i), (ii) & (e)(6)(i). DDMAC requests that Bayer immediately cease the dissemination of violative promotional materials for Levitra, YAZ, and Mirena, such as those described above. Please submit a written response to this letter on or before April 9, 2009, stating whether you intend to comply with this request, listing all promotional materials (with the 2253 submission date) in use for these drugs as of the date of this letter, identifying which of these materials contain violations such as those described above, and explaining your plan for discontinuing use of such materials. Finally, we encourage you to review your promotional materials for the other prescription drug products that Bayer promotes in the United States and to discontinue or revise any materials with the same or similar violations, and request that your response address this issue as well. Please direct your response to the undersigned at the Food and Drug Administration, Center for Drug Evaluation and Research, Division of Drug Marketing, Advertising, and Communications, 5901-B Ammendale Road, Beltsville, MD, facsimile at 301-847-8444. In all future correspondence regarding this matter, please refer to MACMIS # 17307 in addition to the NDA numbers. We remind you that only written communications are considered official. The violations discussed in this letter do not necessarily constitute an exhaustive list. It is your responsibility to ensure that your promotional materials for Levitra, YAZ, and Mirena comply with each applicable requirement of the Act and FDA implementing regulations. Sincerely, {See appended electronic signature page} Shefali Doshi, M.D. Regulatory Review Officer Division of Drug Marketing, Advertising, and Communications cc: Casilda Luck-Barnes Senior Manager, Global Regulatory Affairs Schering Corporation 2000 Galloping Hill Road Kenilworth, NJ 07033
  • 5. --------------------------------------------------------------------------------------------------------------------- This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature. --------------------------------------------------------------------------------------------------------------------- /s/ --------------------- Shefali Doshi 3/26/2009 04:39:41 PM